Press Room

Event

Webinar - Nasal powder delivery: Process, formulation and analytical characterization

Start
Thursday, November 30, 2023 - 16:00
End
Thursday, November 30, 2023 - 18:00
Location: Online

Thursday, November 30th, 2023

11:00 am EDT | 4:00 pm GMT | 5:00 pm CEST | 8:00 am PDT

 

Register now

Registrations to the webinar are subject to approval.

 

Featured Hovione experts in this webinar
Webinar_Speakers_Patricia Henriques_Hovione
Webinar_Speakers_Antonio Serodio
Patrícia Henriques, M.Sc.
Scientist
Inhalation and Advanced Drug Delivery
Hovione		 António Serôdio, M.Sc.
Analytical Scientist
Analytical Development
Hovione

 

This webinar will address the most relevant solutions for nasal powder development covering both process and formulation optimization, as well as the analytical characterization, under an integrated development approach. 

Powders for nasal delivery have been recognized as advantageous dosage forms over liquids due to increased stability and residence time on nasal mucosa, with improved bioavailability. However, the scientific community still struggles with the existing gaps between formulation composition, particle engineering and nasal absorption. 

This presentation will cover different formulation platforms, focusing on the delivery of poorly soluble drugs, aiming to address the pharmacokinetics requirements of the target drug and indication. Different particle engineering strategies including spray drying and process optimization will be addressed, as well as physical and chemical characterization of nasal powders and advanced performance characterization methodologies that are able to predict in vivo behavior in nasal powder early development. The formulation-process-performance integrated approach is designed to maximize rate and extent of drug absorption while maintaining safety, being able to address a diversified array of diseases. 
Register today!

 

Key Learning Objectives:

  • Gain insights on novel formulation development strategies for nasal powders, able to deliver drugs with challenging physicochemical profiles;
  • Understand the potential of spray drying capabilities for boosting targeted nasal delivery of powders; 
  • Discover analytical characterization techniques, for differentiated formulations, to further understand product properties that affect drug delivery;
  • Understand the analytical characterization methodologies for nasal powders;
  • Understand advanced performance methodologies that correlate with in vivo absorption; 
  • Interact with our experts during the live Q&A session.

Who Should Attend:

  • Pharmaceutical researchers and scientists
  • CMC experts on inhalation/nasal drug delivery
  • Business development, portfolio management and technology licensing experts
  • Inhalation product development professionals and therapeutics specialists

Register now and get involved

 

 

 

Also in the Press Room

See All

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Dear Customer, As you may be aware, Portugal and Spain experienced yesterday, April 28 (at approximately 11:30) a widespread power outage. This unexpected event, beyond our control, affected the normal activities at our sites in Portugal. In response, we promptly activated our contingency protocols for this type of situation, prioritizing the safety of facilities and personnel. All ongoing processes were taken to safe hold points, and no new processes were initiated. Our backup power generators ensured continuity of critical functions throughout the duration of the outage, which lasted approximately 11 hours, until the power from the grid was restored at the site. The site began resuming operations gradually through the night making sure all systems being restarted safely and verified to be in good working conditions. We anticipate that most activities will be fully resumed during today. Should you have any specific questions regarding your product or project, we kindly encourage you to contact your Account Manager or Project Manager, who will be glad to assist you. We sincerely appreciate your understanding and continued partnership.      

News
News release, 29 April 2025

Widespread power outage in Portugal - Message to our clients

Apr 29, 2025

In a recent appearance on CNN Portugal’s Pitch – Brand & Content program, Ilda Ventura, Senior Vice President of Human Resources at Hovione, highlighted a powerful reality: 55% of our employees in Science, Technology, Engineering, and Mathematics (STEM) roles are women. At Hovione, we’re proud to foster an environment where women in science thrive - leading innovation, driving progress, and shaping the future of healthcare. But our commitment goes beyond numbers - it’s about creating the right conditions for scientific talent to grow, equally and globally. “I am proud to say that, in our company, there is no gender pay gap between men and women. We empower everyone. Our female and male scientists are all working to find more sustainable, faster, and more productive ways to achieve victories over diseases.” - Ilda Ventura Watch the full edition to learn more about our commitment to women in science at CNNPortugal.pt  (Language: Portuguese)  

Press Clipping
CNN Portugal, 15 March 2025

Ilda Ventura broadcasted on CNN Portugal

Mar 15, 2025

Also in Events

See All